22nd Century Group, Inc. (XXII): Price and Financial Metrics


22nd Century Group, Inc. (XXII): $1.70

-0.04 (-2.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XXII to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XXII POWR Grades


  • XXII scores best on the Growth dimension, with a Growth rank ahead of 23.91% of US stocks.
  • The strongest trend for XXII is in Value, which has been heading down over the past 179 days.
  • XXII ranks lowest in Value; there it ranks in the 0th percentile.

XXII Stock Summary

  • With a price/sales ratio of 12.95, 22nd Century Group Inc has a higher such ratio than 88.71% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for 22nd Century Group Inc; that's greater than it is for only 9.21% of US stocks.
  • With a year-over-year growth in debt of 197.2%, 22nd Century Group Inc's debt growth rate surpasses 94.5% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to 22nd Century Group Inc, a group of peers worth examining would be KRMD, ATEC, ECOR, SIBN, and ACRX.
  • Visit XXII's SEC page to see the company's official filings. To visit the company's web site, go to www.xxiicentury.com.

XXII Valuation Summary

  • In comparison to the median Healthcare stock, XXII's price/earnings ratio is 180.27% lower, now standing at -29.3.
  • Over the past 129 months, XXII's price/sales ratio has gone NA NA.
  • Over the past 129 months, XXII's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for XXII.

Stock Date P/S P/B P/E EV/EBIT
XXII 2021-08-31 19.5 6.7 -29.3 -29.5
XXII 2021-08-30 18.9 6.4 -28.4 -28.5
XXII 2021-08-27 21.7 7.4 -32.6 -32.7
XXII 2021-08-26 19.7 6.7 -29.6 -29.8
XXII 2021-08-25 20.0 6.8 -30.0 -30.2
XXII 2021-08-24 20.8 7.1 -31.3 -31.4

XXII Growth Metrics

    Its 2 year price growth rate is now at -60.2%.
  • Its year over year net income to common stockholders growth rate is now at 27.36%.
  • Its 5 year net cashflow from operations growth rate is now at -91.67%.
XXII's revenue has moved up $4,344,044 over the prior 34 months.

The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 30.948 -22.839 -32.609
2021-09-30 30.296 -21.204 -25.048
2021-06-30 29.795 -16.418 -19.829
2021-03-31 27.859 -14.87 -20.712
2020-12-31 28.111 -15.621 -19.711
2020-09-30 28.06499 -15.51382 -19.50443

XXII's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XXII has a Quality Grade of F, ranking ahead of 0.97% of graded US stocks.
  • XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
  • MO, TPB, and PM are the stocks whose asset turnover ratios are most correlated with XXII.

The table below shows XXII's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.448 0.073 -0.387
2021-03-31 0.485 0.065 -0.480
2020-12-31 0.479 0.051 -0.435
2020-09-30 0.446 0.038 -0.388
2020-06-30 0.425 0.025 -0.494
2020-03-31 0.400 0.015 -0.537

XXII Price Target

For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.33 Average Broker Recommendation 1.5 (Moderate Buy)

XXII Stock Price Chart Interactive Chart >

Price chart for XXII

XXII Price/Volume Stats

Current price $1.70 52-week high $4.05
Prev. close $1.74 52-week low $1.42
Day low $1.67 Volume 3,159,300
Day high $1.76 Avg. volume 2,087,466
50-day MA $1.92 Dividend yield N/A
200-day MA $2.22 Market Cap 365.13M

22nd Century Group, Inc. (XXII) Company Bio


22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.


XXII Latest News Stream


Event/Time News Detail
Loading, please wait...

XXII Latest Social Stream


Loading social stream, please wait...

View Full XXII Social Stream

Latest XXII News From Around the Web

Below are the latest news stories about 22nd Century Group Inc that investors may wish to consider to help them evaluate XXII as an investment opportunity.

22nd Century Group Welcomes Dr. Califf as FDA Commissioner, Urges Action on Menthol and Nicotine in Combustible Cigarettes

FDA’s Rulemaking Process Could Make VLN® Menthol King Reduced Nicotine Cigarettes the Only Menthol Cigarette on the Market Opportunity to Accelerate FDA’s Plan to Cap Nicotine in Cigarettes at Levels Already Achieved in 22nd Century’s VLN® Products BUFFALO, N.Y., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant

Yahoo | February 25, 2022

22nd Century and KeyGene Achieve Breakthrough in Hemp/Cannabis Plant Transformation

New Capabilities Allow 22nd Century to Accelerate Revenue Streams and Create Higher Value Commercial LinesBUFFALO, N.Y., Feb. 23, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today, together with its global plant research partner KeyGene, a breakthrough in its hemp/cannabis plant research leading t

Yahoo | February 23, 2022

Those who invested in 22nd Century Group (NASDAQ:XXII) five years ago are up 131%

While 22nd Century Group, Inc. ( NASDAQ:XXII ) shareholders are probably generally happy, the stock hasn't had...

Yahoo | February 22, 2022

22nd Century Secures USDA Organic Certification for Needle Rock Farms

Organic Certification Enables Premium Pricing and MarginsBUFFALO, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that is has received USDA Organic Certification under 7 CFR Part 205 for its hemp production at Needle Rock Farms. USDA Organic Certification will allow 22nd Century t

Yahoo | February 10, 2022

Dawson James Thinks 22nd Century’s Stock is Going to Recover

Dawson James analyst James McIlree maintained a Buy rating on 22nd Century (XXII – Research Report) on January 24 and set a price target of $8.50. The company's shares closed last Tuesday at $2.36, close to its 52-week low of $1.86. According to TipRanks.com, McIlree is ranked 0 out of 5 stars with an average return of -13.6% and a 33.6% success rate. McIlree covers the Technology sector, focusing on stocks such as Oblong, Vuzix, and SRAX. Currently, the analyst consensus on 22nd Century is a Moderate Buy with an average price target of $8.50.

Brian Anderson on TipRanks | February 9, 2022

Read More 'XXII' Stories Here

XXII Price Returns

1-mo -6.08%
3-mo -3.41%
6-mo -23.77%
1-year -49.40%
3-year -11.46%
5-year -20.93%
YTD -44.98%
2021 40.45%
2020 100.00%
2019 -55.82%
2018 -11.07%
2017 156.88%

Continue Researching XXII

Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:

22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5697 seconds.